SGLT2i恩格列净对2型糖尿病患者心脏保护作用的研究进展  

Cardiovascular Protection of SGLT2i Empagliflozin in Patients with Type 2 Diabetes Mellitus

作　　者：吴易航 张宇辉[1] 张健[1] WU Yihang;ZHANG Yuhui;ZHANG Jian(State Key Laboratory of Cardiovascular Disease,Heart Failure Center,Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)

机构地区：[1]中国医学科学院北京协和医学院阜外医院心力衰竭中心国家重点实验室,北京100037

出　　处：《心血管病学进展》2020年第8期787-789,829,共4页Advances in Cardiovascular Diseases

摘　　要：钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)恩格列净是一种新型降血糖药物,通过抑制肾脏近端小管SGLT2对葡萄糖的重吸收而使血糖降低,适用于治疗2型糖尿病.越来越多的证据显示SGLT2i在降低血糖的同时,对患者心血管系统具有保护作用,已经发表的EMPA-REG OUTCOME试验证明,恩格列净可降低2型糖尿病患者的心血管死亡率,降低心力衰竭住院率及全因死亡.现就其对心脏保护作用做一阐述.Empagliflozin(SGLT2i),a new type of hypoglycemic drug,which inhibits the reabsorption of glucose by the proximal tubular sodium-glucose cotransporter 2(SGLT2)to reduce the blood glucose level,is suitable for the treatment of type 2 diabetes mellitus(T2DM).More and more evidences show that SGLT2 has protective effects on cardiovascular system while lowering blood glucose.EMPAREG OUTCOME test has proved that empagliflozin can reduce cardiovascular mortality,hospitalization rate of heart failure and all-cause death in T2DM patients.This article describes its protective effects on the heart.

关 键 词：恩格列净 钠-葡萄糖协同转运蛋白2 心脏保护 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]